Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.
Persistence of the latent viral reservoir has been recognized as a major obstacle to eradicating human immunodeficiency virus (HIV) in infected individuals receiving antiretroviral therapy. It has been suggested that histone deacetylase inhibitors (HDACis) may purge HIV in the latent viral reservoir. However, the effect of HDACis on the degree and extent of HIV expression in the latent viral reservoir has not been fully delineated. Here we demonstrate that HDACis do not induce HIV production in the latent viral reservoir of aviremic individuals. Therefore, alternative therapeutic strategies may be necessary to eliminate HIV in the latent viral reservoir.
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Jana
J
Blazkova
Tae-Wook
TW
Chun
Bietel W
BW
Belay
Danielle
D
Murray
J Shawn
JS
Justement
Emily K
EK
Funk
Amy
A
Nelson
Claire W
CW
Hallahan
Susan
S
Moir
Paul A
PA
Wender
Anthony S
AS
Fauci
D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology*; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics; D005434:Flow Cytometry; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000235:genetics / Q000254:growth & development / Q000502:physiology*; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D016133:Polymerase Chain Reaction; D018709:Statistics, Nonparametric; D014635:Valproic Acid / Q000627:therapeutic use*; D017735:Virus Latency / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D004279:DNA, Viral; D056572:Histone Deacetylase Inhibitors; D014635:Valproic Acid